Lab Manager | Run Your Lab Like a Business

$3 Million Grant Will Help Custom-Engineer Living Tissue to Fix a Heart

Researchers hope to create new tissue that can replace or protect damaged muscle after a heart attack

by University of Alabama at Birmingham
Register for free to listen to this article
Listen with Speechify

Jianyi “Jay” Zhang, MD, PhDJianyi “Jay” Zhang, MD, PhDPhoto courtesy of the University of Alabama at BirminghamJianyi “Jay” Zhang, MD, PhD, brought his biomedical engineering expertise to the University of Alabama at Birmingham to fix hearts.

His dream—and the dream of other heart experts at major research universities around the world—is creating new tissue that can replace or protect damaged muscle after a heart attack.

Zhang already took a major step toward that goal when he and colleagues protected pigs from post-heart attack heart failure. As described in his 2014 Cell Stem Cell paper, the researchers placed a mat of fibrin over the area where muscle had died and injected three types of cardiovascular cells underneath the mat. This is somewhat akin to starting new lawn by scattering grass seeds beneath a protective layer of hay. The fibrin helped some of the injected cells survive and grow, and they in turn protected the heart from further damage.

Get training in Lab Crisis Preparation and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Lab Crisis Preparation Course

Related Article:  Micro Heart Muscle Created from Stem Cells 

While Zhang’s colleague at the University of Paris Descartes, Philippe Menasché, MD, PhD, is currently testing this approach on five patients, Zhang is launching a new effort in biomedical engineering to improve heart repair, supported by a new $3 million grant from the National Heart, Lung and Blood Institute of the NIH.

Instead of injecting individual cells and hoping they take seed, Zhang plans to robotically build and grow a mat of heart tissue made from individual cells, using a custom 3D printer. Surgeons will then place this custom mat of living cells over the dead, infarcted tissue of the heart, somewhat akin to starting a new lawn by laying sod.

“We will make our own printer, using machinery experts, robotic experts, and computer science experts,” said Zhang, who last fall became the new leader of UAB Biomedical Engineering, a joint department of the UAB School of Medicine and School of Engineering. “A robotic arm will pick up cells of various types from petri dishes and place them onto fine needles that are a few microns apart. The growing cells fuse after three to seven days, and the shape is based on the needles.”

“Then we can lift off the tissue,” Zhang said. “It is scaffold-less tissue engineering. I already have two PhD students on the project.”

The piece of engineered tissue will be “printed-to-order” to match the size and shape of the dead tissue in the heart, as measured by MRI. The prevascularized heart tissue could be quite large, up to 2 by 4 centimeters in area and 5 millimeters thick (about 0.8 by 1.6 by 0.2 inches). All the work must be done under sterile conditions in a culture medium that provides the oxygen and nutrients to keep the cells alive.

Related Article: Delivering Missing Protein Heals Damaged Hearts in Animals

This UAB myocardial tissue patch, done in collaboration with Menasché, Duke University, and the University of Wisconsin, will need to be tested in a pig model before it can move to human trials. “We want to take it to clinical practice in seven years,” Zhang said. “That’s why I came to UAB.”

UAB’s clinical and research expertise in heart electrophysiology will be vital, Zhang says, because the patch could cause heart arrhythmias, or uneven beating, if it interferes with the careful timing of the electrophysiological wave that directs each smooth contraction of the pumping heart. Engineers and clinicians would need to learn how to build the 3D tissue to avoid any complications.

As Zhang expands UAB capacity in tissue engineering, he is also bringing experts to the UAB campus for the annual, NIH-sponsored Cardiovascular Tissue Engineering Workshop that he leads.

In 2015, before Zhang came to UAB, the Zhang-led group of physicians and scientists met at Stanford University, and a perspective piece on the five central challenges to realizing heart repair, “Distilling complexity to advance cardiac tissue engineering,” was published June 8 in the journal Science Translational Medicine. Besides Zhang, authors include researchers from the University of Minnesota, Duke University, Harvard Medical School, Stanford University, the University of Paris Descartes, the University of Washington, the University of Toronto, Georg-August University Göttingen, and Columbia University.

The workshop met at UAB last March for the 2016 meeting, and will again meet at UAB in 2017.

Details of the research

After a heart attack, the heart muscle cells around the edge of the infarcted scar of the left ventricle, the most powerful pump chamber of the heart, get overstretched. Weeks, months or years later this can cause an enlargement of the heart called post-infarction left ventricle remodeling. This leads to heart failure.

Groundwork for producing the engineered tissue meant to prevent remodeling relies on research progress with stem cells, cells that have the ability to differentiate into different types of cells. The 2014 Cell Stem Cell paper, for example, used a combination of three types of cardiovascular cells derived from human induced pluripotent stem cells—cardiomyocytes, endothelial cells, and smooth muscle cells. The fibrin patch was also engineered to release insulin-like growth factor.

Related Article: Scientists Regenerate Heart Muscle in Primates

The cardiomyocytes were able to integrate into the heart and generate organized muscle structure, while the endothelial and smooth muscle cells contributed to heart blood vessels. Pigs getting this trilineage cell transplant had significant improvements in left ventricular function, myocardial metabolism, and density of arterioles that branch out from a heart artery. The transplant also reduced infarct size, ventricular wall stress, and apoptosis, or programmed cell death. Furthermore, the treatment did not produce arrhythmias.

For the clinical test with human patients in Paris, Menasché is using trilineage cells derived from human embryonic stem cells.

At UAB, Zhang holds the T. Michael and Gillian Goodrich Endowed Chair of Engineering Leadership.